- Japanese encephalitis (JE), a viral infection occurring in many areas of Asia and in a few areas of the western Pacific, is acquired through the bite of an infected mosquito.
- Risk is extremely low for short-stay travelers and all those who stay in urban areas or have brief daytime excursions to rural farming areas but is increased for long-stay travelers (with extensive unprotected outdoor, evening/nighttime exposure) going to rural areas in affected countries, especially during JE virus (JEV) transmission season.
- Symptoms include sudden high fever, nausea, headache, and altered mental status.
- Consequences of infection may include convulsions, muscular paralysis, difficulty breathing, coma, and death.
- Prevention includes wearing long sleeves and long pants and observing personal protective measures against mosquito bites.
- JE vaccine (Ixiaro) is given as 2 doses (7 to 28 days apart in persons 2 months and older depending on age at administration) at least 1 week prior to potential exposure.
- Vaccine side effects are most commonly injection-site reactions, fever, headache, and muscle aches.
- Duration of vaccine protection is 10 years or longer following an initial booster (given at least 1 year after the initial 2 doses). No further booster dose is recommended.
JE is a potentially severe viral infection occurring mainly in the local population throughout south-central, southeastern, and eastern Asia and in parts of the western Pacific and is transmitted via the bite of infected mosquitoes. JE is the leading cause of mosquito-borne encephalitis (brain inflammation) in local populations in rural farming areas of these countries. However, in countries with high vaccination coverage, JE occurrence is significantly reduced.
JE occurs in a wide belt from Japan and northern coastal China, throughout southeastern Asia, and across India to Pakistan and more recently in Tibet and the mountain districts in Nepal. JE is also present throughout the Western Pacific islands, from Indonesia to Papua New Guinea and as far north as the Philippines.
Risk is highest in rural agricultural areas (and occasionally near/within urban centers) that are often associated with rice cultivation and flood irrigation.
Elevation and local variations in rainfall and temperature affect mosquito breeding and seasonality of transmission. In temperate areas of Asia, the prevalence of human JEV infection increases toward the end of the summer rains and usually peaks in the summer and fall. In the subtropics and tropics (including Indonesia, the Philippines, southern Thailand, and southern Vietnam), seasonality varies with monsoon rains and irrigation practices and may be prolonged or even occur throughout the year.
Fewer than 100 cases of JE have been reported in travelers from nonendemic countries going to affected areas of Asia since the 1970s (1973-2017). Most cases were acquired in Thailand (mainly Phuket and the Chiang Mai valley) followed by Indonesia (mainly Bali), China, and the Philippines (in descending order of incidence). No travel-related cases have been reported among business or short-stay travelers visiting only urban areas.
JEV is transmitted to humans through the bite of infected evening-biting and night-biting mosquitoes that breed in rice fields and feed most often outdoors. Mosquitoes acquire the virus when they bite pigs and wading birds (in rural farms) that carry JEV; domestic pigs are the main source of infection for mosquitoes that transmit JEV to humans.
Risk is very low for short-stay travelers and persons who confine their travel to urbanized areas or who have brief daytime exposures during common tourist excursions. However, cases may be sporadic and have been reported (albeit rarely) in short-stay visitors traveling out of season whose only rural travel had been to beach resorts.
Risk of JE infection in travelers cannot be inferred from the incidence of JE among residents of JE-endemic countries, which may be lower due to vaccination rates or natural immunity acquired from previous infection among the population. However, expatriates and long-stay travelers (> 1 month) in rural areas are likely at a similar risk to the susceptible (unvaccinated) resident population where JE is prevalent.
Persons with extensive unprotected outdoor, evening, or nighttime exposure (e.g., biking, hiking, camping, and certain occupational activities) in rural areas might be at high risk even if their trip is brief.
Symptoms most commonly appear approximately 5 to 15 days following exposure and include sudden high fever, abdominal pain, nausea, vomiting, headache, generalized weakness, and altered mental status.
Consequences of Infection
JEV infection can lead to convulsions, abdominal pain, breathing difficulties, seizures, mild tremors, poor concentration, memory problems, brain inflammation, and coma. Tremors, slowed movement, rigid muscles, impaired balance, and paralysis may also occur. Death occurs in about 20% to 30% of symptomatic cases.
Need for Medical Assistance
Travelers who develop symptoms (especially altered mental status) of JE infection during travel or within 15 days of leaving a risk area should seek urgent medical attention.
Personal protective measures are the main prevention strategy. Mosquitoes that transmit JEV (Culex spp.) are generally night biters but have peak biting activity at dusk and again at dawn. Regardless of vaccination status, travelers should be especially vigilant in applying repellent during peak biting activity times. Treat outer clothing, boots, tents, and sleeping bag liners with permethrin (or other pyrethroid) when traveling in a very high-risk area for JE. See Insect Precautions.
An injectable vaccine (Ixiaro) is widely available in many countries and is approved for persons 2 months and older. Several single-dose live vaccines are available in endemic areas of Asia as well as in Australia.
The most common vaccine side effects of Ixiaro are injection-site reactions, fever, headache, and muscle aches. Fever, irritability, and diarrhea are most common in infants and children younger than 12 years. Allergic reactions (both immediate and delayed) to the vaccine have occurred.
Persons with underlying medical conditions or those who have concerns about the vaccine should speak to their health care provider before vaccine administration.
Ixiaro vaccine is given to travelers as follows:
- Children aged 2 months through 17 years: 2 doses, given 28 days apart.
- Adults aged 18-65 years: 2 doses, given 7 to 28 days apart.
- Adults 65 years and older: 2 doses, given 28 days apart.
- Doses should be completed at least 1 week before potential exposure.
A booster dose may be given at least 1 year after completion of the primary vaccination series if ongoing exposure or re-exposure to JEV is expected. Duration of protection is 10 years or longer.